Brian Joseph Mog, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antigens, Neoplasm | 8 | 2024 | 1994 | 0.710 |
Why?
|
Receptors, CCR2 | 1 | 2019 | 215 | 0.620 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2024 | 2549 | 0.490 |
Why?
|
Antibodies, Bispecific | 3 | 2021 | 196 | 0.460 |
Why?
|
Peptides | 2 | 2019 | 4342 | 0.310 |
Why?
|
Nanoparticles | 1 | 2019 | 1955 | 0.300 |
Why?
|
Leukemia, T-Cell | 1 | 2024 | 101 | 0.230 |
Why?
|
Neoplasms | 5 | 2024 | 22158 | 0.220 |
Why?
|
T-Lymphocytes | 5 | 2024 | 10191 | 0.220 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 2 | 2024 | 800 | 0.210 |
Why?
|
HLA-B7 Antigen | 1 | 2021 | 50 | 0.200 |
Why?
|
Lymphoma, T-Cell | 1 | 2024 | 304 | 0.190 |
Why?
|
HLA-A2 Antigen | 1 | 2021 | 211 | 0.180 |
Why?
|
Antibodies, Neoplasm | 1 | 2021 | 281 | 0.170 |
Why?
|
Mutant Proteins | 1 | 2021 | 491 | 0.160 |
Why?
|
Loss of Heterozygosity | 1 | 2021 | 662 | 0.160 |
Why?
|
Protein Engineering | 1 | 2021 | 550 | 0.150 |
Why?
|
Lymphoproliferative Disorders | 1 | 2021 | 533 | 0.140 |
Why?
|
Chemokine CCL2 | 1 | 2019 | 604 | 0.140 |
Why?
|
Immunoconjugates | 1 | 2024 | 954 | 0.130 |
Why?
|
ras Proteins | 1 | 2021 | 1053 | 0.130 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1089 | 0.130 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 1742 | 0.130 |
Why?
|
Antibodies | 1 | 2023 | 2421 | 0.120 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2021 | 938 | 0.120 |
Why?
|
COS Cells | 3 | 2021 | 1129 | 0.120 |
Why?
|
Inflammasomes | 1 | 2019 | 525 | 0.120 |
Why?
|
DNA Mutational Analysis | 1 | 2021 | 4108 | 0.100 |
Why?
|
Down-Regulation | 1 | 2019 | 2913 | 0.100 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 36430 | 0.100 |
Why?
|
Reactive Oxygen Species | 1 | 2019 | 2137 | 0.100 |
Why?
|
NF-kappa B | 1 | 2019 | 2488 | 0.090 |
Why?
|
HLA Antigens | 3 | 2021 | 1371 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2021 | 2911 | 0.090 |
Why?
|
Cell Line, Tumor | 2 | 2024 | 16966 | 0.090 |
Why?
|
Mice | 5 | 2024 | 81474 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2811 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3638 | 0.080 |
Why?
|
Immunotherapy | 2 | 2021 | 4649 | 0.080 |
Why?
|
Animals | 8 | 2024 | 168388 | 0.070 |
Why?
|
Contrast Media | 1 | 2019 | 5310 | 0.070 |
Why?
|
Macrophages | 1 | 2019 | 5768 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2024 | 3590 | 0.060 |
Why?
|
Mice, Knockout | 1 | 2019 | 14409 | 0.060 |
Why?
|
Atherosclerosis | 1 | 2019 | 3413 | 0.060 |
Why?
|
Gene Expression Regulation | 1 | 2021 | 11900 | 0.050 |
Why?
|
HLA-A Antigens | 1 | 2023 | 226 | 0.050 |
Why?
|
Immunotherapy, Adoptive | 2 | 2024 | 1469 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5303 | 0.050 |
Why?
|
Mutation | 6 | 2021 | 30044 | 0.050 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2023 | 398 | 0.050 |
Why?
|
Receptors, Interleukin-7 | 1 | 2021 | 40 | 0.050 |
Why?
|
Signal Transduction | 1 | 2024 | 23427 | 0.050 |
Why?
|
Single-Chain Antibodies | 1 | 2021 | 111 | 0.040 |
Why?
|
Histidine | 1 | 2021 | 308 | 0.040 |
Why?
|
Peptide Library | 1 | 2021 | 347 | 0.040 |
Why?
|
Lymphocyte Activation | 2 | 2021 | 5491 | 0.040 |
Why?
|
Alleles | 2 | 2021 | 6909 | 0.040 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 2021 | 445 | 0.040 |
Why?
|
Humans | 13 | 2024 | 761326 | 0.040 |
Why?
|
Jurkat Cells | 1 | 2021 | 739 | 0.040 |
Why?
|
Cross Reactions | 1 | 2021 | 818 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2021 | 616 | 0.040 |
Why?
|
Arginine | 1 | 2021 | 933 | 0.040 |
Why?
|
Cell Line | 2 | 2021 | 15599 | 0.040 |
Why?
|
Immunoprecipitation | 1 | 2019 | 878 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2021 | 13333 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2021 | 1825 | 0.030 |
Why?
|
DNA, Neoplasm | 1 | 2021 | 1745 | 0.030 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2019 | 825 | 0.030 |
Why?
|
Oncogenes | 1 | 2021 | 1223 | 0.030 |
Why?
|
Epitopes | 1 | 2021 | 2504 | 0.030 |
Why?
|
Genome | 1 | 2023 | 1740 | 0.030 |
Why?
|
Immunologic Memory | 1 | 2021 | 1359 | 0.030 |
Why?
|
Protein Conformation | 1 | 2021 | 3969 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2021 | 1805 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2019 | 2193 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1589 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2021 | 6086 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2021 | 4280 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2448 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2021 | 13446 | 0.020 |
Why?
|
Protein Binding | 1 | 2021 | 9351 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2021 | 5114 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 3873 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4576 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2021 | 18962 | 0.020 |
Why?
|
Male | 1 | 2019 | 360621 | 0.010 |
Why?
|
Female | 2 | 2024 | 392485 | 0.010 |
Why?
|